CKS2 Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a full length recombinant CKS2.
|Application ||WB, E|
|Calculated MW||9860 Da|
|Other Names||Cyclin-dependent kinases regulatory subunit 2, CKS-2, CKS2|
|Target/Specificity||CKS2 (AAH06458, 1 a.a. ~ 79 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||CKS2 Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CKS2 protein binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function. The CKS2 mRNA is found to be expressed in different patterns through the cell cycle in HeLa cells, which reflects specialized role for the encoded protein.
Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Shen DY, et al. Liver Int, 2010 Jan. PMID 19845855.Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. Kang MA, et al. J Cancer Res Clin Oncol, 2009 Jun. PMID 19034516.Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Martinsson-Ahlz?n HS, et al. Mol Cell Biol, 2008 Sep. PMID 18625720.Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Lan Y, et al. Int J Cancer, 2008 Aug 1. PMID 18498131.Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. Bertheau P, et al. PLoS Med, 2007 Mar. PMID 17388661.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.